Literature DB >> 20082873

Association between serum gamma-glutamyltransferase and acute ischemic nonembolic stroke in elderly subjects.

Panagiotis Korantzopoulos1, Petros Tzimas, Kallirroi Kalantzi, Michael Kostapanos, Konstantinos Vemmos, John Goudevenos, Moses Elisaf, Haralampos Milionis.   

Abstract

BACKGROUND AND AIMS: Elevated serum gamma-glutamyltransferase (GGT) levels have been proposed as an independent predictor for cardiovascular morbidity and mortality. The aim of this study was to determine whether GGT levels are associated with acute ischemic/nonembolic stroke in a case-control study of elderly subjects.
METHODS: A total of 163 patients >70 years of age (88 men) admitted due to a first-ever acute ischemic/nonembolic stroke and 166 volunteers (87 men) without a history of cardiovascular disease were included. The association between GGT and stroke was determined by multivariate logistic regression modelling after adjusting for potential confounding factors.
RESULTS: GGT levels were higher in subjects with metabolic syndrome (MetS) and correlated with MetS individual components including insulin resistance. Stroke patients showed higher concentrations of GGT compared with controls. In univariate analysis, crude odds ratio (OR) for GGT was 1.06/1 IU/L increase (95% CI, 1.03-1.09; p<0.001). Compared to subjects with GGT levels in the lowest quartile, those within the highest quartile had a 4.7-times increase in the odds of experiencing an ischemic stroke (95% CI 2.39-9.11, p<0.001). This association remained significant after controlling for all potential confounders (adjusted OR, 2.90, 95% CI, 1.35-6.27; p=0.007). Analysis of interaction between MetS and GGT showed that subjects with MetS had a 1.08 higher odds/1 IU/L increase in GGT to experience an ischemic stroke [adjusted OR, 1.08 (95% CI, 1.04-1.12; p<0.001).
CONCLUSIONS: There are positive associations between serum GGT and first ischemic/nonembolic stroke in individuals >70 years of age independent of established risk factors for cardiovascular disease and concurrent metabolic abnormalities. 2009 IMSS. Published by Elsevier Inc.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20082873     DOI: 10.1016/j.arcmed.2009.07.012

Source DB:  PubMed          Journal:  Arch Med Res        ISSN: 0188-4409            Impact factor:   2.235


  10 in total

Review 1.  Benefit-risk assessment of rosuvastatin in the treatment of atherosclerosis and related diseases.

Authors:  Michael S Kostapanos; Christos V Rizos; Moses S Elisaf
Journal:  Drug Saf       Date:  2014-07       Impact factor: 5.606

Review 2.  Current role of fenofibrate in the prevention and management of non-alcoholic fatty liver disease.

Authors:  Michael S Kostapanos; Anastazia Kei; Moses S Elisaf
Journal:  World J Hepatol       Date:  2013-09-27

3.  Fenofibrate in primary biliary cirrhosis: a pilot study.

Authors:  E N Liberopoulos; M Florentin; M S Elisaf; D P Mikhailidis; E Tsianos
Journal:  Open Cardiovasc Med J       Date:  2010-04-28

4.  The relation of high fat diet, metabolic disturbances and brain oxidative dysfunction: modulation by hydroxy citric acid.

Authors:  Kamal A Amin; Hamdy H Kamel; Mohamed A Abd Eltawab
Journal:  Lipids Health Dis       Date:  2011-05-14       Impact factor: 3.876

5.  Changes of liver enzymes and bilirubin during ischemic stroke: mechanisms and possible significance.

Authors:  Antonio Muscari; Andrea Collini; Elisa Fabbri; Marco Giovagnoli; Chiara Napoli; Valentina Rossi; Luca Vizioli; Andrea Bonfiglioli; Donatella Magalotti; Giovanni M Puddu; Marco Zoli
Journal:  BMC Neurol       Date:  2014-06-06       Impact factor: 2.474

6.  Liver function parameters in hip fracture patients: relations to age, adipokines, comorbidities and outcomes.

Authors:  Leon Fisher; Wichat Srikusalanukul; Alexander Fisher; Paul Smith
Journal:  Int J Med Sci       Date:  2015-01-01       Impact factor: 3.738

7.  Non-alcoholic fatty liver disease, liver biomarkers and stroke risk: The Reasons for Geographic and Racial Differences in Stroke cohort.

Authors:  Kristine S Alexander; Neil A Zakai; Steven D Lidofsky; Peter W Callas; Suzanne E Judd; Russell P Tracy; Mary Cushman
Journal:  PLoS One       Date:  2018-03-12       Impact factor: 3.240

8.  Increased concentration of serum gamma-glutamyl transferase in ischemic stroke patients.

Authors:  Teja Ram Kalirawna; Jitendra Rohilla; Shyam Sunder Bairwa; Sunil Kumar Gothwal; Pinki Tak; Rajesh Jain
Journal:  Brain Circ       Date:  2021-05-29

9.  Can we use serum gamma-glutamyl transferase levels to predict early mortality in stroke?

Authors:  Emine Akinci; Nurettin Özgür Doğan; Haluk Gümüş; Nazire Belgin Akilli
Journal:  Pak J Med Sci       Date:  2014-05       Impact factor: 1.088

10.  Gamma-glutamyl transferase levels in patients with acute ischemic stroke.

Authors:  Nurbanu Gurbuzer; Eren Gozke; Zeliha Ayhan Basturk
Journal:  Cardiovasc Psychiatry Neurol       Date:  2014-08-18
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.